Huntington Bancshares
HBAN
$15.32
-0.33%
Huntington Bancshares is a regional US bank holding company with over $280 billion in assets, operating a full suite of consumer deposit and lending services alongside commercial offerings that include payments, investment management, capital markets, equipment financing, and treasury management. As one of the larger US regional banks, Huntington competes primarily against super-regional peers and money-center banks in the Midwest and Southeast, differentiating itself through a relationship-banking model and a growing national specialty-lending footprint. The current investor narrative centers on the bank's aggressive balance-sheet expansion, with Q2 2026 revenue up 37.7% year over year to $4.17 billion and diluted shares outstanding rising from roughly 1.48 billion to 1.98 billion, signaling a major acquisition or capital raise that has reshaped the franchise. At the same time, the stock has been a notable laggard, down 6.2% over the past year versus a 16.0% gain for the S&P 500, as investors debate whether the integration-related earnings dilution and margin pressure are temporary or structural. Management's ability to deliver on the $1.73 consensus EPS estimate for the coming year while digesting a substantially larger balance sheet is the central debate driving sentiment.…
HBAN
Huntington Bancshares
$15.32
Investment Opinion: Should I buy HBAN Today?
The synthesized recommendation is a Hold with a value bias, reflecting the deep valuation discount and unanimous analyst buy consensus, but tempered by significant integration risks and technical weakness. The consensus target price of $19.17 implies 25.1% upside, and the forward PE of 8.69x is well below the sector average, suggesting the stock is undervalued if earnings materialize. However, the stock's persistent underperformance and the 33.8% share dilution create a high degree of uncertainty that warrants caution.
Supporting evidence for a Hold includes the 37.7% year-over-year revenue growth in Q2 2026, the 3.96% dividend yield with a sustainable 45.9% payout ratio, and the 1.05x price-to-book ratio that is near the low end of its historical range. The forward PE of 8.69x represents a 29.4% discount to the trailing PE of 12.30x, implying the market expects significant earnings growth. Additionally, the PEG ratio of 0.90 suggests the stock is trading below its growth-adjusted fair value, and the consensus EPS estimate of $1.73 is tightly clustered between $1.72 and $1.75, indicating high confidence in near-term earnings.
The biggest risks that could invalidate the thesis include a failure to achieve the $1.73 EPS estimate, further margin compression, and a breakdown below the 52-week low of $14.82. The rating would upgrade to Buy if the stock demonstrates a base above $15 and the forward PE compresses below 8x, or if the bank reports two consecutive quarters of EPS growth exceeding 10% quarter-over-quarter. Conversely, a downgrade to Sell would occur if revenue growth decelerates below 10% year-over-year or if the dividend payout ratio exceeds 60%, signaling potential cuts. Relative to its history and peers, HBAN appears undervalued, but the market is pricing in substantial execution risk, making it a cautious hold for value-oriented investors.
Sign up to view all
HBAN 12-Month Price Forecast
The forward-looking view is neutral with a value tilt, as the stock's deep valuation discount and high dividend yield offer a margin of safety, but the integration risks and technical downtrend warrant caution. The key driver will be whether the bank can deliver on the $1.73 EPS estimate, which would likely catalyze a re-rating toward the analyst target. If earnings disappoint or margins compress further, the stock could retest its 52-week low. I would upgrade to bullish if the stock forms a base above $15 and the forward PE remains below 9x, and downgrade to bearish if revenue growth decelerates below 10% or the dividend payout ratio exceeds 60%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Huntington Bancshares's 12-month outlook, with a consensus price target around $19.16 and implied upside of +25.1% versus the current price.
Average Target
$19.16
0 analysts
Implied Upside
+25.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $23
Analyst target range
Huntington is covered by 20 analysts with a consensus recommendation of "buy" and a recommendation mean of 1.71 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a bullish tilt among the sell-side community. The average target price of $19.17 implies approximately 25.1% upside from the current price of $15.32, a substantial expected return that stands in stark contrast to the stock's recent price action. The consensus EPS estimate of $1.73 for the coming year, against the current trailing EPS of $0.086, implies the analyst community expects a dramatic earnings recovery, which is the linchpin of the bullish thesis. The target range spans from a low of $17.00 to a high of $22.50, a spread of $5.50 or 32.4% of the average target, which signals meaningful disagreement about the company's trajectory. The high target of $22.50 implies roughly 46.9% upside and would require both multiple expansion and successful integration of the bank's expanded balance sheet, likely predicated on achieving operating leverage and hitting the $1.73 EPS estimate. The low target of $17.00 still implies 11.0% upside, suggesting that even the most conservative analyst sees the stock as undervalued at current levels, though that target may assume margin compression or slower-than-expected growth. Recent institutional ratings show a mix of reaffirmations: Truist Securities and DA Davidson maintained Buy ratings in September 2026, while B of A Securities downgraded to Neutral from Buy in July 2026 and Morgan Stanley moved to Equal Weight from Overweight in July 2026, indicating some analysts are turning more cautious even as the consensus remains positive. The tight clustering of EPS estimates ($1.72 to $1.75) contrasts with the wide price target range, suggesting analysts agree on near-term earnings but disagree on the appropriate multiple, which is typical for a bank undergoing a major transformation.
Bulls vs Bears: HBAN Investment Factors
The bear case currently has stronger evidence due to the stock's persistent underperformance, significant share dilution, and technical weakness, but the bull case is supported by deep valuation discounts and a unanimous analyst consensus that sees substantial upside. The single most important tension is whether the bank can successfully integrate its recent expansion and deliver on the $1.73 EPS estimate, which would justify a re-rating; failure to do so could lead to further downside. The market appears to be pricing in a high degree of skepticism, creating a potential value opportunity if execution improves. However, the burden of proof remains on management to demonstrate that the revenue growth translates into sustainable per-share earnings growth.
Bullish
- Deep valuation discount to peers: HBAN trades at 8.69x forward earnings and 1.05x book value, well below the 11-14x forward PE and 1.2-1.5x book typical for quality regional banks. The PEG ratio of 0.90 further suggests the stock is priced below its growth-adjusted fair value.
- Analyst consensus sees 25% upside: With 20 analysts covering the stock, the consensus rating is 'buy' (mean 1.71) and the average target price of $19.17 implies 25.1% upside from $15.32. Even the lowest target of $17.00 still offers 11.0% upside, indicating a favorable risk/reward skew.
- Revenue growth accelerating sharply: Q2 2026 revenue surged 37.7% year over year to $4.17 billion, up from $3.03 billion in Q2 2025, with sequential growth from $3.25 billion in Q4 2025 to $3.77 billion in Q1 2026 to $4.17 billion in Q2 2026. This top-line momentum, though largely inorganic, demonstrates the scale of the expanded franchise.
- Attractive dividend yield near historic high: The dividend yield of 3.96% is near the high end of its historical range and is supported by a payout ratio of 45.9%, which leaves ample room for continued dividends even if earnings fluctuate. This provides a steady income stream while awaiting a turnaround.
Bearish
- Severe stock underperformance versus market: HBAN is down 6.2% over the past year while the S&P 500 gained 16.0%, a relative underperformance of 22.2%. Year-to-date, the stock has fallen 12.4% versus a 14.2% gain for the index, a 26.5% relative shortfall, indicating persistent negative momentum.
- Massive share dilution erodes per-share value: Diluted shares outstanding jumped from approximately 1.48 billion in Q2 2025 to 1.98 billion in Q2 2026, a 33.8% increase. This dilution has kept EPS growth muted, with Q2 2026 EPS of $0.38 only modestly above the $0.34 reported a year earlier despite a 37.7% revenue increase.
- Earnings recovery hinges on aggressive estimates: The consensus EPS estimate of $1.73 for the coming year implies a dramatic recovery from the trailing EPS of $0.086. This wide gap between trailing and forward earnings suggests the market is pricing in a best-case scenario that may be difficult to achieve.
- Technical downtrend with limited support: The stock is trading just 10.6% above its 52-week low of $14.82 and 21.3% below its 52-week high of $19.46, with a 3-month decline of 14.3% that is steeper than the 1-year decline. The accelerating downtrend suggests further weakness may lie ahead.
HBAN Technical Analysis
Huntington Bancshares is in a clear downtrend, with the current price of $15.32 sitting just 10.6% above its 52-week low of $14.82 and 21.3% below its 52-week high of $19.46, placing it in the bottom quartile of its annual range. The 1-year price change of -6.24% and year-to-date decline of -12.36% confirm persistent negative momentum, and the stock's relative strength versus the S&P 500 is deeply negative at -22.24% over one year and -26.53% year to date. This positioning near the lower end of the range suggests the market is pricing in meaningful fundamental deterioration rather than a temporary pullback, and the burden of proof is on the bulls to demonstrate a base is forming. Recent momentum has deteriorated further, with the 1-month change of -7.88% and 3-month change of -14.27% both worse than the 1-year figure, indicating the downtrend is accelerating rather than stabilizing. The 1-month relative strength of -10.00% versus the S&P 500's +2.12% gain shows pronounced underperformance, and the 3-month relative strength of -17.40% versus the index's +3.13% underscores that this is a sustained divergence, not a one-month anomaly. The 6-month change of -6.47% versus the S&P 500's +14.59% (a -21.06% relative spread) reinforces that capital has been rotating out of this name consistently across timeframes. Key technical support rests at the 52-week low of $14.82, roughly 3.3% below the current price; a breakdown below that level would likely trigger momentum-driven selling and open the door to new lows. Resistance sits at the 52-week high of $19.46, approximately 27.0% above the current price, and reclaiming even the mid-range near $17 would require a decisive change in trend. With a beta of 0.972, the stock is slightly less volatile than the broader market, meaning the underperformance is driven by stock-specific factors rather than amplified market beta; the maximum drawdown of -22.06% over the period reflects the severity of the de-rating.
Beta
0.97
0.97x market volatility
Max Drawdown
-22.1%
Largest decline past year
52-Week Range
$15-$19
Price range past year
Annual Return
-6.2%
Cumulative gain past year
| Period | HBAN Return | S&P 500 |
|---|---|---|
| 1m | -7.9% | +1.9% |
| 3m | -14.3% | +3.9% |
| 6m | -6.5% | +12.1% |
| 1y | -6.2% | +19.2% |
| ytd | -12.4% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HBAN Fundamental Analysis
Huntington's revenue trajectory has inflected sharply higher, with Q2 2026 revenue of $4.17 billion representing 37.7% year-over-year growth versus Q2 2025's $3.03 billion, and the sequential progression from $3.25 billion in Q4 2025 to $3.77 billion in Q1 2026 to $4.17 billion in Q2 2026 shows accelerating top-line momentum. However, this growth is largely inorganic, as diluted shares outstanding jumped from approximately 1.48 billion in Q2 2025 to 1.98 billion in Q2 2026, and the segment mix shows Consumer & Regional Banking at $1.92 billion and Commercial Banking at $994 million, with Treasury/Other a -$72 million drag. The critical question is whether this expanded revenue base can generate commensurate per-share earnings, since EPS of $0.38 in Q2 2026 is only modestly above the $0.34 reported in Q2 2025 despite the much larger revenue base. Profitability remains solid but is under pressure on a per-share basis: Q2 2026 net income of $727 million compares to $536 million a year earlier, a 35.6% increase, and the gross margin of 64.9% is up from 60.6% in Q2 2025, while the net margin of 17.4% is roughly flat versus 17.7% a year ago. The operating margin of 21.5% in Q2 2026 is consistent with the 21.1% reported in Q2 2025, suggesting that while the bank is absorbing a much larger cost base, it is managing expenses effectively enough to hold margins steady. The net income ratio of 17.4% and the trailing net margin of 17.7% are respectable for a regional bank, but the ROE of 9.08% remains below the 10-12% range that typically commands premium valuations in the sector. The balance sheet tells a more nuanced story: debt-to-equity of 0.76 is moderate, but the current ratio of 0.19 is unusually low and reflects the bank's liability-sensitive balance sheet rather than a liquidity crisis, while the ROE of 9.08% and ROA of 0.98% are modest. Free cash flow on a trailing basis is $2.96 billion, but quarterly FCF has been volatile, ranging from $400 million in Q1 2026 to $1.25 billion in Q2 2026, and the Q2 2026 cash flow statement shows a net cash decrease of $10.4 billion driven by $6.5 billion in debt repayment and $7.2 billion in investment purchases. The dividend payout ratio of 45.9% and dividend yield of 3.96% are attractive for income investors, but the sustainability of that payout depends on the bank's ability to generate consistent operating cash flow, which has been lumpy.
Quarterly Revenue
$4.2B
2026-06
Revenue YoY Growth
+37.7%
YoY Comparison
Gross Margin
64.9%
Latest Quarter
Free Cash Flow
$3.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HBAN Overvalued?
Because Huntington is profitable with trailing net income of $727 million in the most recent quarter and positive EPS of $0.086 on a trailing basis, the PE ratio is the appropriate primary valuation metric. The trailing PE of 12.30x compares to a forward PE of 8.69x, a 29.4% discount that implies the market expects significant earnings growth over the next twelve months, consistent with the consensus EPS estimate of $1.73. This wide trailing-to-forward gap is the market's way of saying that current earnings are depressed relative to the bank's normalized earnings power, likely due to integration costs or elevated provisioning. On a peer-relative basis, the price-to-book ratio of 1.05x is modest for a regional bank and suggests the market values Huntington close to its tangible book value, while the PEG ratio of 0.90 indicates the stock is trading below its growth-adjusted fair value. The PS ratio of 2.06x and EV/EBITDA of 12.28x are less informative for a bank but do not flag obvious overvaluation. Compared to the broader regional banking sector, where quality names often trade at 1.2-1.5x book and 11-14x forward earnings, Huntington's 1.05x book and 8.69x forward PE represent a meaningful discount, likely reflecting concerns about the integration of its recent expansion and the dilution from the share count increase. Historically, Huntington's PE ratio has ranged from roughly 7.0x in early 2023 to 21.2x in late 2023, with the current 12.30x sitting near the middle of that band but well above the 2023 lows. The price-to-book ratio of 1.05x is near the lower end of its historical range, which has oscillated between roughly 0.81x and 1.20x over the past three years, suggesting the market is pricing in either a value opportunity or a permanent impairment of the franchise. The dividend yield of 3.96% is near the high end of its historical range (which has ranged from roughly 0.95% to 1.76% in the data provided, though the current figure appears elevated relative to that history), reinforcing the income-oriented value case.
PE
12.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant given the bank's recent balance-sheet expansion. The debt-to-equity ratio of 0.76 is moderate, but the current ratio of 0.19 is unusually low and reflects a liability-sensitive balance sheet that could strain liquidity if funding conditions tighten. The 33.8% increase in diluted shares outstanding from 1.48 billion to 1.98 billion has diluted per-share earnings, with Q2 2026 EPS of $0.38 only slightly above the $0.34 from a year earlier despite a 37.7% revenue jump. Additionally, the ROE of 9.08% and ROA of 0.98% are below sector benchmarks, indicating that the expanded asset base is not yet generating commensurate returns. Free cash flow has been volatile, ranging from $400 million in Q1 2026 to $1.25 billion in Q2 2026, which could pressure the dividend if operating cash flow remains lumpy.
Market and competitive risks are elevated due to the stock's deep underperformance and sector rotation dynamics. HBAN has underperformed the S&P 500 by 22.2% over the past year and 26.5% year-to-date, and its beta of 0.972 suggests that the decline is driven by stock-specific issues rather than broad market weakness. The regional banking sector faces intense competition from larger money-center banks and fintech disruptors, which could pressure net interest margins and fee income. Recent analyst actions, including downgrades by B of A Securities and Morgan Stanley in July 2026, highlight growing caution about the integration risks and the sustainability of the revenue growth. If the Federal Reserve maintains higher interest rates for longer, funding costs could rise further, compressing margins and delaying the expected earnings recovery.
The worst-case scenario involves a failed integration, continued margin compression, and a breakdown below the 52-week low of $14.82. If the bank misses its $1.73 EPS estimate and analysts revise targets downward, the stock could retest its 52-week low, representing a decline of approximately 3.3% from the current price of $15.32. However, a more severe sell-off could push the stock toward the 2023 lows, where the PE ratio touched 7.0x; applying that multiple to trailing EPS of $0.086 would imply a price near $0.60, but that is unrealistic given the forward earnings power. A more plausible bear case target is the analyst low of $17.00, which is actually above the current price, suggesting that even the most conservative analyst sees limited downside. The maximum drawdown over the past year was -22.06%, and a similar decline from the current price would take the stock to around $11.94, though that would require a significant deterioration in fundamentals. In a worst-case scenario, investors could lose 20-30% from the current price if the integration fails and the bank cuts its dividend.
FAQ
The key risks include: 1) Integration risk from the recent expansion, with diluted shares up 33.8% to 1.98 billion, which has muted EPS growth to $0.38 in Q2 2026 despite a 37.7% revenue increase. 2) Margin compression risk, as the net interest margin could narrow if funding costs rise, especially with the current ratio at 0.19 indicating a liability-sensitive balance sheet. 3) Earnings disappointment risk, as the consensus EPS estimate of $1.73 is far above the trailing EPS of $0.086, leaving little room for error. 4) Market and sector risk, with the stock's beta of 0.972 and relative underperformance of 22.2% over the past year, making it vulnerable to further rotation out of regional banks. These risks are ranked from highest to lowest severity.
The 12-month forecast includes three scenarios: Bull case (30% probability) targets $19.17-$22.50, assuming successful integration and EPS meeting the $1.73 estimate. Base case (50% probability) targets $17.00-$19.17, assuming steady progress and stable margins. Bear case (20% probability) targets $14.82-$17.00, assuming integration challenges and margin compression. The base case is most likely, with the key assumption that EPS meets the consensus estimate of $1.73 and no further dilution occurs. The stock is currently trading at $15.32, so the base case implies upside of 11-25%.
HBAN appears undervalued based on multiple metrics. The forward PE of 8.69x is well below the 11-14x range typical for quality regional banks, and the price-to-book ratio of 1.05x is near the low end of its historical range of 0.81x to 1.20x. The PEG ratio of 0.90 indicates the stock is trading below its growth-adjusted fair value. However, the trailing PE of 12.30x is near the middle of its historical band, suggesting that the market is pricing in significant earnings growth to justify the current price. If the bank meets the $1.73 EPS estimate, the stock would be undervalued; if it fails, the valuation could be justified. Overall, the market is pricing in a high degree of skepticism, creating a potential value opportunity.
HBAN presents a mixed risk/reward profile. On the positive side, the stock trades at a deep discount to peers with a forward PE of 8.69x and a price-to-book of 1.05x, while offering a 3.96% dividend yield. The analyst consensus target of $19.17 implies 25.1% upside, and the PEG ratio of 0.90 suggests undervaluation relative to growth. However, the stock has significantly underperformed the market, down 6.2% over the past year versus a 16.0% gain for the S&P 500, and faces integration risks from a 33.8% increase in share count. For value-oriented investors with a long-term horizon and tolerance for volatility, HBAN could be a good buy at current levels, but it is not suitable for those seeking quick gains or low risk.
HBAN is more suitable for long-term investment, given its value orientation, dividend yield, and turnaround potential. The stock's beta of 0.972 indicates slightly lower volatility than the market, but it has experienced a maximum drawdown of -22.06% over the past year, suggesting short-term trading could be risky. The dividend yield of 3.96% and payout ratio of 45.9% make it attractive for income-focused investors who can wait for the integration to bear fruit. Earnings visibility is low in the near term due to integration costs, but improves over a 2-3 year horizon. A suggested minimum holding period is 2-3 years to allow for the full realization of synergies and earnings recovery.